Wuhan YZY Biopharma Co., Ltd. () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Wuhan YZY Biopharma Co., Ltd.

Why is Wuhan YZY Biopharma Co., Ltd. ?

Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 0%

Poor long term growth as Net Sales has grown by an annual rate of 440.50% and Operating profit at 16.50% over the last 5 years
High Debt Company with a Debt to Equity ratio (avg) at times

Flat results in Jun 25

ROCE(HY) Lowest at -723.86%
DEBT-EQUITY RATIO (HY) Highest at 34.68 %
INTEREST(Q) Highest at HKD 2.56 MM

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -18.31%, its profits have risen by 43.1%

Below par performance in long term as well as near term

Along with generating -18.31% returns in the last 1 year, the stock has also underperformed Hang Seng Hong Kong in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Wuhan YZY Biopharma Co., Ltd. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Wuhan YZY Biopharma Co., Ltd.

-18.31%

-0.58

61.37%

Hang Seng Hong Kong

27.08%

1.35

20.07%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

440.50%

EBIT Growth (5y)

16.50%

EBIT to Interest (avg)

-72.24

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

0.03

Sales to Capital Employed (avg)

0.90

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

18.72

EV to EBIT

-5.28

EV to EBITDA

-5.62

EV to Capital Employed

18.17

EV to Sales

5.21

PEG Ratio

Dividend Yield

ROCE (Latest)

-344.13%

ROE (Latest)

-325.55%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

Bullish

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bearish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

6What is working for the Company

NET PROFIT(HY)

Higher at HKD -63.2 MM

INVENTORY TURNOVER RATIO(HY)

Highest at 12.64 times

RAW MATERIAL COST(Y)

Fallen by -1,431% (YoY

DEBTORS TURNOVER RATIO(HY)

Highest at 13.88 times

-4What is not working for the Company

ROCE(HY)

Lowest at -723.86%

DEBT-EQUITY RATIO (HY)

Highest at 34.68 %

INTEREST(Q)

Highest at HKD 2.56 MM

Here's what is working for Wuhan YZY Biopharma Co., Ltd.

Net Profit

Higher at HKD -63.2 MM

than preceding 12 month period ended Jun 2025

MOJO Watch

In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (HKD MM)

Inventory Turnover Ratio

Highest at 12.64 times and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Debtors Turnover Ratio

Highest at 13.88 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost

Fallen by -1,431% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Wuhan YZY Biopharma Co., Ltd.

Interest

Highest at HKD 2.56 MM

in the last five periods and Increased by 15.21% (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (HKD MM)

Debt-Equity Ratio

Highest at 34.68 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio